PureTech Enters CAR-T With Vor BioPharma
This article was originally published in Start Up
Executive Summary
PureTech Health says its new start-up Vor BioPharma is advancing a novel approach to chimeric antigen receptor (CAR) T-cell therapy that has the potential to broaden the science's applicability and success rate in other cancers – but it's not willing to say exactly how it will do that.